146 related articles for article (PubMed ID: 32815678)
1. Glucocorticoid-Induced Osteoporosis Prevention in Polymyalgia Rheumatica Patients.
Swami T; Molloy C
Ir Med J; 2020 Mar; 113(3):36. PubMed ID: 32815678
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica.
Naranjo A; López R; García-Magallón B; Cáceres L; Francisco F; Jiménez-Palop M; Ojeda-Bruno S
Rheumatol Int; 2014 Oct; 34(10):1459-63. PubMed ID: 24728030
[TBL] [Abstract][Full Text] [Related]
3. Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica Is Uncommon but May Be Enhanced by Amino Bisphosphonates.
Giollo A; Rossini M; Bettili F; Ghellere F; Fracassi E; Idolazzi L; Gatti D; Viapiana O
J Rheumatol; 2019 Mar; 46(3):318-322. PubMed ID: 30385701
[TBL] [Abstract][Full Text] [Related]
4. Trabecular Bone Score Is a Useful Parameter for the Prediction of Vertebral Fractures in Patients With Polymyalgia Rheumatica.
Kim HA; Lee HY; Jung JY; Suh CH; Chung YS; Choi YJ
J Clin Densitom; 2020; 23(3):373-380. PubMed ID: 31174962
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study.
Rossini M; Viapiana O; Vitiello M; Malavolta N; La Montagna G; Maddali Bongi S; Di Munno O; Nuti R; Manzini CU; Ferri C; Bogliolo L; Mathieu A; Cantatore F; Del Puente A; Muratore M; Grassi W; Frediani B; Saviola G; Delvino P; Mirone L; Ferraccioli G; Tripi G; Piazza I; Gatti D
Reumatismo; 2017 May; 69(1):30-39. PubMed ID: 28535619
[TBL] [Abstract][Full Text] [Related]
6. Effects of quality indicator monitoring for glucocorticoid-induced osteoporosis and trends of drug treatment in a Japanese hospital.
Suda M; Suyama Y; Ohde S; Tsuda T; Sawada H; Kishimoto M; Okada M
Int J Rheum Dis; 2018 May; 21(5):975-981. PubMed ID: 29878618
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid-Induced Osteoporosis.
Buckley L; Humphrey MB
N Engl J Med; 2018 Dec; 379(26):2547-2556. PubMed ID: 30586507
[No Abstract] [Full Text] [Related]
8. Osteoporosis prophylaxis in patients receiving chronic glucocorticoid therapy.
Sadat-Ali M; Alelq AH; Alshafei BA; Al-Turki HA; Abujubara MA
Ann Saudi Med; 2009; 29(3):215-8. PubMed ID: 19448373
[TBL] [Abstract][Full Text] [Related]
9. BSR and BHPR guidelines for the management of polymyalgia rheumatica.
Dasgupta B; Borg FA; Hassan N; Barraclough K; Bourke B; Fulcher J; Hollywood J; Hutchings A; Kyle V; Nott J; Power M; Samanta A;
Rheumatology (Oxford); 2010 Jan; 49(1):186-90. PubMed ID: 19910443
[No Abstract] [Full Text] [Related]
10. Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides-Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort.
Palmowski A; Wiebe E; Muche B; Hermann S; Dejaco C; Matteson EL; Buttgereit F
Cells; 2022 Feb; 11(3):. PubMed ID: 35159345
[TBL] [Abstract][Full Text] [Related]
11. Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis-prevalence and clinical approach.
Borresen SW; Thorgrimsen TB; Jensen B; Hilsted L; Bartels EM; Feldt-Rasmussen U; Locht H
Rheumatology (Oxford); 2020 Oct; 59(10):2764-2773. PubMed ID: 32031663
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and treatment of osteoporosis in nonmetastatic breast cancer].
Eiken PA; Hansen M; Kristensen B; Langdahl BL; Abrahamsen B
Ugeskr Laeger; 2011 Feb; 173(8):577-81. PubMed ID: 21333258
[TBL] [Abstract][Full Text] [Related]
13. Use of bisphosphonates and dual-energy X-ray absorptiometry scans in the prevention and treatment of glucocorticoid-induced osteoporosis in rheumatology.
Wall E; Walker-Bone K
QJM; 2008 Apr; 101(4):317-23. PubMed ID: 18270228
[TBL] [Abstract][Full Text] [Related]
14. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
15. No permanent reduction in bone mineral density during treatment of polymyalgia rheumatica and temporal arteritis using low dose corticosteroids.
Haugeberg G; Myklebust G; Dovland H; Mikkelsen B; Gran JT
Scand J Rheumatol; 2000; 29(3):163-9. PubMed ID: 10898068
[TBL] [Abstract][Full Text] [Related]
16. Polymyalgia rheumatica and giant-cell arteritis.
Praderio L; Di Comite G; Saporiti N
N Engl J Med; 2002 Dec; 347(25):2083-5; author reply 2083-5. PubMed ID: 12494941
[No Abstract] [Full Text] [Related]
17. [Modifications of markers of bone resorption in patients affected by glucocorticoid induced osteoporosis (GIOP) treated with neridronate].
Benucci M; Dolenti S; Saviola G; Manfredi M
Recenti Prog Med; 2006 Jan; 97(1):24-7. PubMed ID: 16535926
[TBL] [Abstract][Full Text] [Related]
18. Polymyalgia rheumatica and giant cell arteritis.
Subrahmanyan P; Dasgupta B
Br J Hosp Med (Lond); 2006 May; 67(5):240-3. PubMed ID: 16729627
[TBL] [Abstract][Full Text] [Related]
19. [Current topics over updating guidelines on the management and treatment of glucocorticoid-induced osteoporosis].
Suzuki Y
Clin Calcium; 2014 Mar; 24(3):417-24. PubMed ID: 24576939
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid-induced osteoporosis preventive care in rheumatology patients.
Koller G; Katz S; Charrois TL; Ye C
Arch Osteoporos; 2019 Feb; 14(1):16. PubMed ID: 30723883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
